UMR216, Institut de Recherche pour le Développement, Paris, France.
PLoS One. 2012;7(4):e35342. doi: 10.1371/journal.pone.0035342. Epub 2012 Apr 13.
To investigate the consequences of intermittent preventive treatment (IPTp) timing on birth weight, we pooled data from two studies conducted in Benin between 2005 and 2010: a prospective cohort of 1037 pregnant women and a randomised trial comparing sulfadoxine-pyrimethamine (SP) to mefloquine in 1601 women. A total of 1439 women (752 in the cohort and 687 in the SP arm of the randomised trial) who delivered live singletons were analysed. We showed that an early intake of the first SP dose (4 months of gestation) was associated with a lower risk of LBW compared to a late intake (6-7 months of gestation) (aOR = 0.5 p = 0.01). We also found a borderline increased risk of placental infection when the first SP dose was administered early in pregnancy (aOR = 1.7 p = 0.1). This study is the first to investigate the timing of SP administration during pregnancy. We clearly demonstrated that women who had an early intake of the first SP dose were less at risk of LBW compared to those who had a late intake. Pregnant women should be encouraged to attend antenatal visits early to get their first SP dose and a third dose of SP could be recommended to cover the whole duration of pregnancy and to avoid late infections of the placenta.
为了研究间歇性预防治疗(IPTp)时机对出生体重的影响,我们汇集了 2005 年至 2010 年在贝宁进行的两项研究的数据:一项是 1037 名孕妇的前瞻性队列研究,另一项是比较磺胺多辛-乙胺嘧啶(SP)和甲氟喹在 1601 名妇女中的随机试验。共有 1439 名(队列中的 752 名和随机试验 SP 臂中的 687 名)分娩活单胎的妇女进行了分析。我们表明,与妊娠 6-7 个月(晚期)相比,妊娠 4 个月(早期)首次服用 SP 剂量与 LBW 的风险降低相关(aOR=0.5,p=0.01)。我们还发现,当首次 SP 剂量在妊娠早期给予时,胎盘感染的风险略有增加(aOR=1.7,p=0.1)。这是第一项研究怀孕期间 SP 给药时间的研究。我们清楚地表明,与晚期摄入相比,早期摄入首剂 SP 的妇女 LBW 的风险较低。应鼓励孕妇尽早进行产前检查以获得首剂 SP,并建议给予第三剂 SP,以覆盖整个妊娠期间,避免胎盘晚期感染。